If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.50 (0.696%)
Market Cap: £684.34m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Result of AGM

11 Jul 2024 11:05

RNS Number : 0617W
Dr. Martens PLC
11 July 2024
 

11 July 2024

DR. MARTENS PLC

RESULT OF ANNUAL GENERAL MEETING

11 JULY 2024

 

The Company announces the results of voting at its Annual General Meeting held earlier today and confirms that all resolutions were duly passed on a poll with majorities as set out below.

Resolutions 1 to 16 were proposed as Ordinary Resolutions and resolutions 17 to 20 as Special Resolutions.

Resolution

 

 

 

VotesFor

(note 1)

 

%

 

 

Votes Against

(note 1)

 

%

 

 

VotesTotal

 

 

Votes Withheld

(note 2)

% Voting

Capital Instructed

01

Receive the 2024 Annual Report and Accounts

789,653,948

99.87%

1,016,107

0.13%

790,670,055

389,119

82.18

02

Approve the Directors' Remuneration Report

784,551,256

99.18%

6,479,754

0.82%

791,031,010

28,164

82.22

03

Approve the Remuneration Policy

784,540,438

99.18%

6,484,634

0.82%

791,025,072

34,102

82.22

04

Approve the Final Dividend

790,899,254

99.98%

138,398

0.02%

791,037,652

21,522

82.22

05

Elect Giles Wilson

790,575,687

99.94%

472,252

0.06%

791,047,939

11,235

82.22

06

Re-elect Paul Mason

739,380,746

98.45%

11,649,105

1.55%

751,029,851

40,029,322

78.06

07

Re-elect Kenny Wilson

782,546,350

99.38%

4,857,639

0.62%

787,403,989

3,655,185

81.84

08

Re-elect Andrew Harrison

784,035,245

99.11%

7,011,325

0.89%

791,046,586

12,587

82.22

09

Re-elect Ian Rogers

784,033,188

99.11%

7,013,122

0.89%

791,046,586

12,587

82.22

10

Re-elect Lynne Weedall

782,969,980

98.98%

8,079,606

1.02%

791,049,586

9,587

82.22

11

Re-elect Robyn Perriss

783,169,527

99.00%

7,880,059

1.00%

791,049,586

9,587

82.22

12

Re-elect Tara Alhadeff

775,890,657

98.53%

11,583,929

1.47%

787,474,586

3,584,587

81.85

13

Re-appoint PricewaterhouseCoopers LLP as auditor

790,431,574

99.92%

619,491

0.08%

791,051,065

8,109

82.22

14

Authorise the Audit & Risk Committee to determine the Auditor's remuneration

790,886,095

99.98%

160,465

0.02%

791,046,560

12,614

82.22

15

Authorise the Company and its subsidiaries to make political donations

782,418,912

99.36%

5,046,388

0.64%

787,465,300

3,593,874

81.85

16

Authorise allotment of shares

781,095,005

99.30%

5,488,607

0.70%

786,583,612

4,475,562

81.76

17

Authorise general disapplication of pre-emption rights*

744,775,869

94.58%

42,685,045

5.42%

787,460,914

3,598,260

81.85

 18

Authorise additional disapplication of pre-emption rights*

743,752,064

94.45%

43,708,850

5.55%

787,460,914

3,598,260

81.85

19

Authorise purchase of own shares*

772,052,557

97.61%

18,934,341

2.39%

790,986,898

72,276

82.22

20

Authorise calling of general meetings on 14 days' notice*

788,373,014

99.66%

2,680,102

0.34%

791,053,116

6,058

82.22

*Special Resolution

 

The votes of independent shareholders on the resolutions concerning the election or re-election of the Independent Non-Executive Directors are set out below:

Resolution

 

 

VotesFor

 

%

 

Votes Against

 

%

 

VotesTotal

 

Votes Withheld

 

% Independent

Capital Instructed

08

Re-elect Andrew Harrison

414,092,821

98.34%

7,011,325

1.66%

421,104,146

12,587

71.12%

09

Re-elect Ian Rogers

414,091,024

98.33%

7,013,122

1.67%

421,104,146

12,587

71.12%

10

Re-elect Lynne Weedall

413,027,540

98.08%

8,079,606

1.92%

421,107,146

9,587

71.13%

11

Re-elect Robyn Perriss

413,227,087

98.13%

7,880,059

1.87%

421,107,146

9,587

71.13%

 

Notes:

1. Votes "For" and "Against" are expressed as a percentage of votes received.

2. A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3. As at 6.30pm on 9 July 2024 the Company had a total of 962,080,090 ordinary shares with voting rights in issue. The total independent voting capital, used to calculate the votes of independent shareholders on resolutions 8 to 11, was 592,062,882.

4. In accordance with Listing Rule 9.6.2R, copies of the resolutions passed as special business will shortly be available for inspection on the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Enquiries

Company Secretariat

Paul Rolling, Assistant Company Secretary +44 7584 243562

 

Investors and analysts

Bethany Barnes, Director of Investor Relations +44 7825 187465

bethany.barnes@drmartens.com

Media

Gill Hammond, Director of Communications +44 7384 214248

 

H/Advisors Maitland +44 20 7379 5151

Katharine Spence +44 7384 535739

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGPUCUMUPCGUG
Date   Source Headline
2nd Oct 20257:00 amRNS-RUAE distribution partnership and LATAM expansion
16th Sep 202511:55 amRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHolding(s) in Company
2nd Sep 20259:30 amRNSDirector/PCA Shareholding
29th Aug 20254:22 pmRNSTotal Voting Rights
12th Aug 20253:17 pmRNSDirector/PDMR Shareholding
1st Aug 202511:51 amRNSTotal Voting Rights
28th Jul 20258:53 amRNSDirector/PDMR Shareholding
14th Jul 20253:08 pmRNSDirector/PDMR Shareholding
10th Jul 202510:58 amRNSResult of 2025 AGM
10th Jul 20257:00 amRNSAGM Trading Update
4th Jul 20251:56 pmRNSTotal Voting Rights
17th Jun 202510:00 amRNSDirector/PDMR Shareholding
17th Jun 20259:00 amRNSAnnual Financial Report
12th Jun 20254:13 pmRNSDirector/PDMR Shareholding
5th Jun 20257:00 amRNSFinal Results
2nd Jun 20252:05 pmRNSBlock listing Interim Review
30th May 202510:52 amRNSTotal Voting Rights
27th May 20258:45 amRNSDirector Declaration
14th May 20252:20 pmRNSDirector/PDMR Shareholding
1st May 20254:02 pmRNSTotal Voting Rights
16th Apr 20254:00 pmRNSDirector/PDMR Shareholding
9th Apr 20253:00 pmRNSDirector/PDMR Shareholding
31st Mar 20259:38 amRNSTotal Voting Rights
26th Mar 202510:00 amRNSDirector/PDMR Shareholding
12th Mar 20252:26 pmRNSDirector/PDMR Shareholding
28th Feb 202511:01 amRNSTotal Voting Rights
12th Feb 20254:35 pmRNSDirector/PDMR Shareholding
12th Feb 20257:00 amRNSAppointment of Non-Executive Directors
31st Jan 202510:36 amRNSTotal Voting Rights
27th Jan 20257:00 amRNSQ3 FY25 Trading Statement
15th Jan 20256:14 pmRNSDirector/PDMR Shareholding
2nd Jan 202512:02 pmRNSTotal Voting Rights
20th Dec 20243:07 pmRNSHolding(s) in Company
13th Dec 202411:54 amRNSDirector/PDMR Shareholding
12th Dec 20247:00 amRNSBlock Listing Application
2nd Dec 202410:43 amRNSBlock listing Interim Review
2nd Dec 202410:10 amRNSTotal Voting Rights
28th Nov 20247:01 amRNSConfirmation of new CEO start date
28th Nov 20247:00 amRNSHalf-year Report
12th Nov 20243:56 pmRNSDirector/PDMR Shareholding
31st Oct 20243:23 pmRNSTotal Voting Rights
15th Oct 20243:19 pmRNSDirector/PDMR Shareholding
2nd Oct 20241:55 pmRNSDirector/PDMR Shareholding
30th Sep 202410:24 amRNSTotal Voting Rights
26th Sep 20242:00 pmRNSTransaction by PCA of PDMR
25th Sep 20247:00 amRNSHolding(s) in Company
24th Sep 202410:53 amRNSDirector/PDMR Shareholding
23rd Sep 20244:31 pmRNSHolding(s) in Company
12th Sep 20243:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.